Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline
3. Antiviral activities of antibodies in vitro
4. Anti-viral activities of antibodies overview
5. Neutralization
6. Neutralization assay
7. HIV-1 pseudovirus neutralization assay
8. Neutralization curves JRCSF
9. Neutralization curves - 01US056
10. How do antibodies neutralize viruses?
11. Early history of antibody neutralizaion
12. NAbs to HIV are directed to Env spikes
13. Neutralization and affinity to envelope trimers
14. HIV makes contact with a target cell
15. Antibody interferes with viral attachment
16. Must antibodies bind to the virus to neutralize?
17. Flag Tag introduction to the V4 loop
18. HIV-1 YU2 glycoprotein ineffectivity
19. Neutralizing HIV-1 YU2 variants by IgG1b12 Ab
20. Neutralizing HIV-1 YU2 variants by -FLAG Ab
21. Inhibition of infection by antibody binding to HIV-1
22. Example: neutralizing Ab against influenza
23. Correlation between number of Abs and virion size
24. Rhinovirus neutralization
25. Kinetic effects in Ab neutralization
26. Component mediated lysis and phagocytosis
27. Further activities against free virus
28. Antibody activities against infection
29. Activities against infected cells
30. Antibody-mediated enhancement of infection
31. Infection enhancement for HIV
32. Antiviral activities of antibodies in vivo
33. Two scenarios for antibody activity in vivo
34. Protection
35. Human HIV infection in SCID mice
36. Neutralization and protection in huPBL-SCID mice
37. IgG1 b12 antibody protects macaques
38. Neutralization/protection correlation for mAb b12
39. Requirements for passive antibody protection
40. Antibody protection against Ebola virus
41. Location for Ebola virus study
42. Documentation in ASM News
43. Human mAb KZ52 neutralizes Ebola
44. Protection ability of KZ52
45. Ebola virus challenge in the macaque model
46. Neutralizing antibody prophylaxis in macaques
47. Effective use of monoclonal antibodies
48. Evidence for other mechansims of protection
49. Protection ability of non-neutralizing Abs
50. Antibodies in vaccine protection
51. Therapy
52. Investigating Ab efficacy in therpay
53. Treating HIV-infected mice with a 3-Ab cocktail
54. Escape from each of the mAbs
55. Interplay between Ab levels and viral variants
56. Viral strategies for avoiding antibody responses
57. Envelope structural features
58. Conclusions (1)
59. Conclusions (2)

Topics Covered

• Anti-viral activities of antibody in vitro
• Neutralization
• Mechanisms of neutralization
• Other activities against free viruses
• Activities against infected cells
• Antibody mediated enhancement
• Anti-viral activities of antibodies in vivo
• Protection
• Antibodies in therapy of viral infection
• Viral strategies for avoiding antibody responses

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Immunology
• Microbiology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Prof. Dennis Burton has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.